Alnylam Pharmaceuticals Projects Strong Revenue Growth Ahead

Alnylam Pharmaceuticals anticipates non-GAAP profitability by 2025, with projected revenue growth of 31% for 2025. This positive outlook could influence investor confidence and stock prices.

Date: 13-01-2025

AI Rating: 7

Positive Outlook for Non-GAAP Operating Income
Alnylam Pharmaceuticals Inc. (ALNY) is expecting to achieve non-GAAP operating income profitability by 2025. This implication of future profitability is a significant factor that could enhance investor sentiment and potentially lead to an increase in stock prices.

Revenue Growth Guidance
The company has provided guidance for combined net product revenues from its key products: ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, estimating revenues between $2.050 billion and $2.250 billion for the full year 2025. This represents an impressive growth rate of 31% at the midpoint compared to 2024. Such robust projected revenue growth is a strong indicator of the company's potential to enhance profitability and can positively impact stock prices.

Quarterly Revenue Performance
Preliminary global net product revenues for the fourth quarter show ONPATTRO generating approximately $56 million and AMVUTTRA generating about $287 million. Additionally, GIVLAARI and OXLUMO are expected to deliver approximately $65 million and $44 million, respectively. These figures suggest that the company is on a positive trajectory regarding its sales performance, further supporting the upward trend in revenue expectations.

Stocks: ALNY